Literature DB >> 2232893

Rationales for a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cytosine arabinoside.

V Heinemann1, U Jehn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2232893

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  6 in total

Review 1.  Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.

Authors:  Milly E de Jonge; Alwin D R Huitema; Jan H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.

Authors:  Nikolas Herold; Sean G Rudd; Linda Ljungblad; Kumar Sanjiv; Ida Hed Myrberg; Cynthia B J Paulin; Yaser Heshmati; Anna Hagenkort; Juliane Kutzner; Brent D G Page; José M Calderón-Montaño; Olga Loseva; Ann-Sofie Jemth; Lorenzo Bulli; Hanna Axelsson; Bianca Tesi; Nicholas C K Valerie; Andreas Höglund; Julia Bladh; Elisée Wiita; Mikael Sundin; Michael Uhlin; Georgios Rassidakis; Mats Heyman; Katja Pokrovskaja Tamm; Ulrika Warpman-Berglund; Julian Walfridsson; Sören Lehmann; Dan Grandér; Thomas Lundbäck; Per Kogner; Jan-Inge Henter; Thomas Helleday; Torsten Schaller
Journal:  Nat Med       Date:  2017-01-09       Impact factor: 53.440

Review 3.  Pharmacokinetic optimisation of anticancer therapy.

Authors:  J Liliemark; C Peterson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

4.  Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine.

Authors:  U Jehn; V Heinemann
Journal:  Ann Hematol       Date:  1993-03       Impact factor: 3.673

5.  In vitro analysis of drug resistance in tumor cells from patients with acute myelocytic leukemia.

Authors:  J Kristensen; B Jonsson; C Sundström; P Nygren; R Larsson
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

6.  SAMHD1 protects cancer cells from various nucleoside-based antimetabolites.

Authors:  Nikolas Herold; Sean G Rudd; Kumar Sanjiv; Juliane Kutzner; Julia Bladh; Cynthia B J Paulin; Thomas Helleday; Jan-Inge Henter; Torsten Schaller
Journal:  Cell Cycle       Date:  2017-04-24       Impact factor: 4.534
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.